Go to the profile of Brightpath Biotherapeutics

Brightpath Biotherapeutics

 

About Brightpath Biotherapeutics

BrightPath Biotherapeutics, formerly GreenPeptide, is a Japan-based clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics. Our pipeline includes cancer peptide vaccine, rejuvenated T cell therapy, and immuno-modulator antibodies. Our basic business model covers research and early clinical development, followed by out-licensing to pharmaceutical companies, so we would like to take an opportunity to introduce our out-licensing candidates. We also search for in-licensing and/or research collaboration opportunities in I/O field.

Therapeutic Areas

Oncology

Technologies

Peptides Regenerative medicine Vaccines

Company Type

Pharmaceutical

State of Ownership

Public

Sponsorship Group

Networker

Influencer Of

Topics

Topics contributed to:

Oncology

Editions participated in:

September 2017 November 2017